However, these methods have limitations such as poor efficiency, cross-reactivity, and the need for sophisticated laboratory equipment and qualified personnel. To mitigate these limitations, a label-free electrochemical glycobiosensor has been established for the detection of anti-GPI IgG and IgM antibodies in serum from toxoplasmosis seropositive patients. The biosensor uses a synthetic GPI phosphoglycan bioreceptor immobilized on screen-printed gold electrodes through a linear alkane thiol phosphodiester. The antigenantibody interaction is detected and quantified by electrochemical impedance spectroscopy (EIS). The glycobiosensor has a linear dynamic range of anti-GPI antibodies in serum ranging from 1.0 to 10.0 IU mL-1, with a limit of detection of 0.31 IU mL-1. This method not only allows for the detection and quantification of IgG and IgM anti-GPI antibodies for the diagnosis of toxoplasmosis, but also holds great potential for the detection of IgG antibodies related to other medical conditions characterized by overexpression of antibodies. The electrochemical method offers new opportunities for diagnosis in decentralized settings. The high performance of the glycobiosensor has been demonstrated by detecting a concentration of antibodies of clinical relevance in serum samples and determining positive serostatus reactive against T. gondii. An augmented glycobiosensor response was related to an increase of toxoplasma antibodies, thus demonstrating that the method is suitable for the diagnosis of acute toxoplasmosis. In summary, the glycobiosensor provides a promising approach for the diagnosis of various medical conditions based on antibody detection, including toxoplasmosis.